Lung Cancer
Conditions
Interventions
PTX 70mg/m2 VNR 20mg/m2 every 3 weeks 2-6 courses
Sponsors
Niigata Lung Cancer Treatment Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 histologically or cytologically confirmed stage IIIB or IV NSCLC. 2 No prior chemotherapy 3 measurable disease 4 age 20=< 5 performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale 6 adequate bone marrow (leukocyte count > 4,000/mm3, <12,000/mm3, neutrophil count > 2,000/mm3, hemoglobin concentration > 9.5g/dL, platelet count > 100,000 /mL), kidney (creatinine < 1.2 mg/dL), liver (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] < 100, total bilirubin < 2.0 mg/dL), and pulmonary (PaO2 > 60 torr) functions.
Exclusion criteria
Exclusion criteria: 1 active concomitant malignancies or infections 2 past history of severe allergic reactions to drugs 3 other serious complications, such as interstitial pneumonia identified by chest X-ray, uncontrolled angina pectoris, myocardial infarction, heart failure, uncontrolled diabetes mellitus, liver cirrhosis or hypertension
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival,safety, toxicity, QOL | — |
Countries
Japan
Contacts
Public ContactHirohisa Yoshizawa
Niigata University Medical and Dental Hospital Bioscience Medical Research Center
Outcome results
None listed